115 related articles for article (PubMed ID: 17015901)
1. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2.
Peng F; Lu X; Janisse J; Muzik O; Shields AF
J Nucl Med; 2006 Oct; 47(10):1649-52. PubMed ID: 17015901
[TBL] [Abstract][Full Text] [Related]
2. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.
Cai H; Wu JS; Muzik O; Hsieh JT; Lee RJ; Peng F
J Nucl Med; 2014 Apr; 55(4):622-8. PubMed ID: 24639459
[TBL] [Abstract][Full Text] [Related]
3. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
4. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
[TBL] [Abstract][Full Text] [Related]
5. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
6. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
[TBL] [Abstract][Full Text] [Related]
7. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a ⁶⁴Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model.
Kim MH; Park JA; Woo SK; Lee KC; An GI; Kim BS; Kim KI; Lee TS; Kim CW; Kim KM; Kang JH; Lee YJ
Int J Oncol; 2015 Mar; 46(3):1159-68. PubMed ID: 25586565
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
11. Theranostics of malignant melanoma with 64CuCl2.
Qin C; Liu H; Chen K; Hu X; Ma X; Lan X; Zhang Y; Cheng Z
J Nucl Med; 2014 May; 55(5):812-7. PubMed ID: 24627435
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride.
Zhang H; Cai H; Lu X; Muzik O; Peng F
Acad Radiol; 2011 Dec; 18(12):1561-8. PubMed ID: 22055798
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.
Oyama N; Ponde DE; Dence C; Kim J; Tai YC; Welch MJ
J Nucl Med; 2004 Mar; 45(3):519-25. PubMed ID: 15001697
[TBL] [Abstract][Full Text] [Related]
16. Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159.
Wang H; Li D; Liu S; Liu R; Yuan H; Krasnoperov V; Shan H; Conti PS; Gill PS; Li Z
J Nucl Med; 2015 Jun; 56(6):908-13. PubMed ID: 25908833
[TBL] [Abstract][Full Text] [Related]
17. A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection.
Hao G; Zhou J; Guo Y; Long MA; Anthony T; Stanfield J; Hsieh JT; Sun X
Amino Acids; 2011 Nov; 41(5):1093-101. PubMed ID: 20221650
[TBL] [Abstract][Full Text] [Related]
18. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
[TBL] [Abstract][Full Text] [Related]
20. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter.
Mitsuoka K; Miyoshi S; Kato Y; Murakami Y; Utsumi R; Kubo Y; Noda A; Nakamura Y; Nishimura S; Tsuji A
J Nucl Med; 2008 Apr; 49(4):615-22. PubMed ID: 18344442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
